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Abstract
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder for which the current
medical therapy is not completely effective. Bovine colostrum (BC) is a biological fluid rich in
bioactive molecules that may have beneficial effects on several gastrointestinal disorders.
The objectives of this study were to assess the preventive effects of BC supplementation in
a mouse model of 2,4,6 trinitrobenzene sulfonic acid (TNBS)-induced colitis using a multi-
disciplinary approach. Specifically, the following parameters were evaluated: (i) disease
activity index (DAI), (ii) histological score, (iii) expression levels of TLR4, anti- and pro-
inflammatory cytokines, and (iv) count of some bacterial species of the intestinal microbiota.
Mice received a daily suspension of BC (BC group, n = 12) or saline solution (control, CN
group, n = 12) for 21 days before the intrarectal inoculation with 1% of TNBS solution. BC
was well tolerated and did not induce any histological damage or clinical symptoms. After
TNBS treatment, BC group showed a reduction of body weight (BW) loss (P<0.01) and his-
tological score (P<0.05) compared to CN. Moreover, the expression levels of TLR4
(P<0.05), IL-1β (P<0.001), IL-8 (P<0.001), and IL-10 (P<0.001) were lower in mice adminis-
tered with BC, while the concentrations of TNF-α did not show any differences between
groups. Finally, the supplementation with BC resulted in a differential response to TNBS
treatment in the bacterial count. In CN group, E. coli and Enterococci increased (P<0.001),
while Anaerobes (P<0.01), Lactobacilli, and Bifidobacteria (P<0.001) reduced. Conversely,
no significant changes in bacterial load were found after the inoculation of TNBS in BC pre-
treated mice. This study confirms that TNBS-induced colitis model in mice is useful for
studying the mechanisms involved in IBD pathogenesis and shows that pre-treatment with
BC reduces the intestinal damages and clinical signs of the colitis. Molecular mechanisms
and intestinal microflora could be involved in the protective effect of colostrum.
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Introduction
Inflammatory bowel diseases (IBD) are a group of chronic inflammatory idiopathic recurrent
disorders of the gastrointestinal tract affecting people worldwide [1]. In humans, Crohn’s dis-
ease (CD) and Ulcerative Colitis (UC) are considered the most dangerous conditions included
in IBD [2]. Although the exact mechanisms that induce the intestinal inflammation are widely
unknown, it is suggested that genetic, environmental, and immunological factors may play a
role in the onset of the disease [3–5].
In physiological conditions, the gastrointestinal tract is colonized by commensal microflora
that confer important host benefit including mucosal barrier, metabolic and immune regula-
tory functions, and it may also be potentially exposed to pathogen organisms [6]. As a conse-
quence, the digestive system should be able to downregulate inflammatory responses to
commensal bacteria while maintaining the capacity to respond to pathogens in order to pre-
serve the immunological homeostasis [7–9].
Recently, a number of studies suggested that changes of the commensal flora can induce a
dysregulation of the intestinal immune response. The shift in the makeup of the intestinal
microbiota to a nonphysiologic composition (dysbiosis) could be involved in the pathogenesis
of IBD [10]. Indeed, colitis can not be induced in germ-free animals [11], and dysbiosis has
been observed in patients affected by IBD [7,12,13].
Microbial agents are recognized by the host immune system through pattern recognition
receptors (PRRs). Toll-like receptors (TLRs) are members of PRRs family expressed in both
the immune and non-immune cells of different tissues, including those of the gastrointestinal
tract [14,15]. TLRs, which are type 1 transmembrane receptors, recognize pathogen-associated
molecular patterns (PAMPs) or more extensively microbe-associated molecular patterns
(MAMPs) such as carbohydrates, lipids, proteins, and nucleic acids derived from bacteria,
viruses, and fungi [16]. To date, various TLRs have been identified in the gastrointestinal tract;
however, TLR2, TLR5, and especially TLR4 are considered to be the most related to the onset
of IBD [17,18].
TLR4 have a significant role in the host defence and are involved in several intestinal func-
tions such as the maintenance of barrier integrity, immune homeostasis, differentiation,
growth as well as the repair of the intestinal epithelium [8,19]. They are expressed on the cell
surface of the intestinal epithelial cells of villi, crypts, and stromal cells [20,21]. TLR4 are
required for the recognition of LPS, which is the major component of the outer membrane of
the cell wall of Gram-negative bacteria [22]. TLR4 are activated by the interaction with a com-
plex constituted by the LPS, LPS-binding protein, and CD14. The activation of the receptor
results in the recruitment of different adaptor proteins, including MyD88, TIRAP, TRIF, and
TRAM, leading to a cascade of complex intracellular signal pathways that results in the activa-
tion of the nuclear factor kB (NF-kB) [23,24]. This induces the transcription of genes involved
in host defence, including those for the inflammatory cytokines such as IL-1β, IL-6, IL-8, and
TNF-α, chemokines, adhesion molecules, acute phase proteins, antigen presenting molecules,
and other inflammatory mediators such as reactive oxygen species as well as nitric oxide in the
effector cells [22,23]. In particular, TNF-α is known to promote inflammation by both inhibit-
ing epithelial repair and increasing apoptosis of the cells, which alters intestinal microbiota
and facilitates luminal translocation [25]. In IBD illness, TNF-α is found in high levels in
mucosa and serum so anti TNF antibody therapy is indeed proved to be a crucial milestone in
its treatment [26].
In addition, the organism possesses anti-inflammatory mechanisms which are meant to
modulate the magnitude of the response against pathogens. Specifically regulatory T cells
(Tregs) are considered a sub-population of T cells, which play a key role in maintaining
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homeostasis and peripheral tolerance towards self and non-self antigens, by secreting high lev-
els of IL-10 and TGF-β [25]. As a matter of fact, studies proved that mice deficient in IL-10
spontaneously develop a T-cell-dependent colitis, whereas TGF-β suppresses a T-cell-mediated
colitis in animals [27]. Moreover, patients with dysfunctional or lack of Tregs develop a severe
intestinal inflammation, while treatment with anti TNF-antibodies restore circulating Tregs to
normal levels [28,29].
Under homeostatic conditions, there is a counterbalance between the production of pro
and anti-inflammatory cytokine. The malfunction of these mediators of inflammation affect
the cellular, vascular, and barrier functions other than the immune response, leading both to a
disruption of the homeostatic mechanisms and to the breakdown of tolerance to the colonic
microflora [19]. In IBD, this leads to a continuous chain reaction with enhanced permeability
followed by luminal antigens translocation and a subsequent pro-inflammatory cytokine pro-
duction that will determine either the onset of a new chronic process or the ongoing of a previ-
ous process [30].
At present, therapy protocols are based on the administration of anti-inflammatory drugs,
immune system suppressors, antibiotics and supplements, which altogether are not curative,
besides, they present many negative secondary effects [31]. A different medical approach to
this disease is required, so novel strategies based on the use of natural products such as dietary
supplements and food components have been emerging in recent years [32–34].
Colostrum is the first milk rich in a wide range of antimicrobial peptides, immune-regulat-
ing components and growth factors with anti-inflammatory and immuno-modulatory proper-
ties [35]. The pivotal functions of colostrum are the following: to provide essential nutritional
components, to reinforce natural defences, to modulate intestinal microflora and immune
responses, and to promote the growth, maturation, and repair of many tissues [36,37].
Recently, several studies have evaluated the effects of BC administration in the prevention and
treatment of various gastrointestinal disorders in different animal species and in humans [38–
42]. Nevertheless, studies concerning the clinical use of BC in IBD are still limited and contro-
versial [43,44].
The objectives of this study were to assess the preventive effects of bovine colostrum supple-
mentation on the colon inflammation in a mouse model of TNBS-induced colitis using a mul-
tidisciplinary approach and combining in vivo and in vitro measurements. More specifically,
the following parameters were evaluated: (i) disease activity index (DAI), (ii) histological fea-
tures, (iii) expression levels of TLR4 and anti- and pro-inflammatory cytokines such as IL-1β,
IL-8, TNF-α, and IL-10, and (iv) count of some bacterial species of the intestinal microbiota.
Materials and methods
Animals
CD-1 male mice at 6 weeks of age, weighting 34.9±2.42 g (Harlan Laboratoires S.r.l., Correz-
zana D’Adda, Milan, Italy) were housed in an ambient with the following controlled parame-
ters: 12 h light/dark cycle, 21±1˚C constant temperature, and 55±10% relative humidity. All
animals were administered standard laboratory chow and water ad libitum. After an acclimati-
zation period of 10 days, mice were included in the experimental trial. All experimental proto-
cols were approved by the Ethical Committee for Animal Experimentation at the University of
Perugia, Italy. Animal care was in compliance with Italian regulations (Ministerial Declaration
116/92) as well as with European Economic Community regulations (O.J. of European Com-
mission L 358/1 12/18/1986). All efforts were made to minimize animal distress and to use
only the number of animals necessary to produce reliable results. A loss of>20% of BW was
considered as the criterion for humane endpoint; no mice reached this criterion.
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Bovine colostrum
We used Nutra Summa Pure Bovine Colostrum Powder1 (Phoenix, Arizona, USA), which
was skimmed, pasteurized, and freeze-dried to ensure minimum denaturation of Ig and of the
other bioactive molecules. The concentrations of IgG were 15–20% while the other ingredients
are shown in S1 Table.
Experiment
S1 Fig illustrates the experimental protocol. CD-1 mice (n = 24) were randomly divided into
two groups (n = 12) and received daily by gavage a suspension containing bovine colostrum
(100 mg of colostrum dissolved in 0.6 mL of saline solution for each mouse, BC group), or the
same volume of saline solution (Control group, CN) for 21 days.
BC suspension was prepared immediately before the administration by reconstituting the
BC powder with saline solution and vortex mixing; subsequently, it was inoculated by plastic
feeding tubes equipped with a 1 ml syringe (2 biological instruments, Basozzo, Varese, Italy).
After 21 days of nutritional treatment, six mice of each group (BC pre-TNBS and CN pre-
TNBS) were sacrificed by cervical dislocation in order to evaluate the effects of colostrum
administration in healthy animals. The other six animals of each group (BC post-TNBS and
CN post-TNBS) were treated with TNBS and sacrificed 3 days later to evaluate preventive
effects of BC supplementation on the induced colitis. In particular, BC post-TNBS and CN
post-TNBS mice were intrarectally inoculated with 150 μl of 1% TNBS solution. TNBS (Sigma-
Aldrich, Milan, Italy) solution was prepared at the moment of use diluting the haptinizing
agent in ethanol 50%. Before the intrarectal inoculation of 1% TNBS solution, mice were fasted
for 24 h and lightly anesthetized with isoflurane (Merial, Milan Italy). A plastic catheter
equipped with a 1 ml syringe (2 biological instruments, Basozzo, Varese, Italy) was lubricated
and advanced through the anus for 3 cm before the release of the TNBS. In order to ensure the
distribution of the TNBS within the colon, the mice were held in a vertical position with the
head downwards for one minute after the injection. Body weight (BW) and health status of
animals were monitored daily.
Determination of disease activity index (DAI)
DAI was determined taking in consideration stool consistency, weight loss, and bleeding as
previously described by Murano et al. [45] combining their score on a scale from 0 to 4 (S2
Table). The parameters were recorded daily after TNBS treatment (day 22–24).
Tissue processing
Mice were euthanized 3 days after the TNBS treatment by cervical dislocation. At autopsy, a
macroscopic evaluation of the whole digestive tract was made. The gastrointestinal tract was
immediately aseptically removed from anus to oesophagus. The large bowel was macroscop-
ically evaluated and then subdivided into caecum, colon, and rectum. Colon was opened longi-
tudinally and the luminal content was removed, immediately placed into an anaerobic
chamber, and homogenized in sterile pre-reduced PBS for the bacteriological assays. Colon
was washed with saline solution, and representative samples of tissue were collected and fixed
in 10% neutral formalin for the histological procedures.
Histological analyses and scoring
Samples of colon were paraffin embedded, cut in 4–5 μm sections and stained with hematoxy-
lin and eosin (H&E; Merk KGa, Darmstadt, Germany).
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Histological scoring was based on a semi-quantitative score system modified by McCafferty
et al. [46]. The following features were graded: extent of destruction of mucosal architecture,
presence and degree of cellular infiltration, and extent of muscle thickening. For each feature,
a score of 0, 1, 2, and 3 was attributed corresponding to normal, mild, moderate, and extensive
damage, respectively. The scores for each feature were summed with a maximum possible
score of 12.
Microbiota analysis
Samples of bowel content were aseptically collected, processed via 10-fold dilution and cul-
tured in triplicate. Chromocult agar and Bile Esculin Azide Agar were used for the count of
aerobes (E.coli, Coliforms, and Enterococci). The plates were incubated in aerobiosis at 37˚ C
for 24–48 hours. Brain heart Infusion agar, Mann Rogosa Sharpe agar (MRS), modified MRS
agar, (0.3% w/v) sodium propionate, 0.2% (w/v) lithium chloride, 0.05% (w/v) cysteine hydro-
chloride, and 5% (v/v) defibrinated sheep blood were used for the development of the anaer-
obes (Lactobacillus spp. and Bifidoacterium spp.). The plates were routinely grown using
anaerojars and Anaerogen sachets (Oxoid) at 37˚C for 48–72 hours. The number of colonies
was counted and expressed as CFU x log/g.
Detection and quantification of gene expression
After rinsing with RNase-free PBS, tissue samples were frozen at -80˚C. RNA was extracted
from paraffin sections of about 10 μm using FFPE RNA Purification Kit (Norgen Biotek
Corp., Ontario, Canada) according to the manufacturer’s instructions with minor adjust-
ments. In order to avoid genomic DNA contamination, the samples were treated with
RNase-Free DNase I Kit (Norgen Biotek Corp) following the manufacturer’s instructions.
Qubit RNA assay (Life Technologies) was used to measure the amount of RNA, and then, the
samples were stored at -80˚ C until use. A quantity of 20 ng of total RNA was reverse tran-
scribed with iSCRIPT cDNA (Bio-Rad, Hercules, CA, USA). To check for genomic DNA con-
tamination, controls without reverse transcriptase were included, according to the producer’s
guidelines.
In order to obtain a total volume of 20 μl for the PCR assay, 1 μl of PrimeTime qPCR IDT
(Integrated DNA Technologies, Coralville, Iowa, USA) 250 nM, 10 μl of ITAQ universal probe
(Bio-Rad, Hercules, CA), and 5 μL of water were mixed. The following PrimeTime IDT were
used for qPCR: IL10 (Mm.PT.58.13531087) TNFα (Mm.PT.58.29509614), IL1ß (Mm.
PT.58.42940223), IL8 (Mm.PT.58.33056956), TLR4 (Mm.PT.58.41780308.g), and ACTB (Mm.
PT.58.33540333).
In the 96-well PCR plate, reagents were mixed with 4 μl of diluted cDNA (1:10). Each sam-
ple was analysed in triplicate. The qPCR analyses were performed with iCycler iQ (Bio-Rad)
following these incubation steps: 95˚C for 30 seconds, 45 cycles at 95˚C for 15 seconds, and
finally 60˚C, reading fluorescence signal. To confirm the amplification, the resulting PCR
product was analyzed by dissociation curves and visualized in an agarose gel. PCR products
were purified and sequenced using a QIAquick PCR Purification Kit (Qiagen Inc., Valencia,
CA, USA). The relative expression genes were normalized to actin B reference gene levels.
Statistical analysis
The data was analysed using the Linear Mixed model in which animals were included as ran-
dom factor [47]. Changes in BW before and after TNBS treatment were evaluated including
the Time as repeated factors and BW at day 1 or day 18 as covariate. These models evaluated
the effects of Time (days before or after TNBS treatment), Group (2 levels: CN and BC groups),
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and the interaction between Group and Time. To analyse influences of TNBS on mRNA
expressions and bacterial counts of the two groups, the models evaluated the effects of TNBS
(2 levels: pre- and post- TNBS treatment), Group (2 levels: CN and BC groups), and their
interaction. Sidak adjustment was used for carrying out multiple comparisons. Diagnostic
graphics were used for testing assumptions and outliers. Results were expressed as estimated
marginal means ± standard error (SE), while raw data were presented in figures. Bacterial
counts were expressed and analysed as log10 CFU per gram of colon samples. Mann-Whitney
test was used to assess DAI and histological scores. Values were expressed as median (Mdn)
and interquartile range (IQR). Statistical analyses were performed with SPSS Statistics version
23 (IBM, SPSS Inc., Chicago, IL, USA). Statistical significance occurred when P 0.05.
Results
Body Weight (BW) and Disease activity index (DAI)
The BW of all mice increased from day 2 to 21 (34.3±0.1 gr and 35.7±0.1 gr at day 2 and 21,
respectively; P<0.001); however, there were no differences between groups (34.9±0.1 gr and
35.0±0.1 gr in CN and BC groups, respectively; P = 0.442). Conversely, after TNBS treatment,
the BW of BC group was higher than CN group (32.6±0.5 gr and 35.4±0.5 gr in CN post-TNBS
and BC post-TNBS groups, respectively; P = 0.003).
After TNBS treatment, 1 of 6 mice died both within CN and BC group. However, although
as a trend, DAI of BC group was lower than CN group (Mdn = 1.7, IQR = 1.3–3.3, and
Mdn = 0.3, IQR = 0.3–1.3 in CN and BC groups, respectively; P = 0.095).
Macroscopic evaluation
At macroscopic examination, colon of BC and CN pre-TNBS mice was normal and did not
show lesions; whereas, colon of CN post-TNBS mice was swollen, oedematous, and thickened,
with evidence of mucosal haemorrhage compared to the BC post-TNBS group at gross
examinations.
Histology
Histological scores of animals sacrificed before TNBS treatment were low in both BC and CN
pre-TNBS groups (Mdn = 3, IQR = 2–4, and Mdn = 1, IQR = 0–1 in CN and BC groups,
respectively; P > 0.05). The histological examination revealed that the colon of the mice of
both groups either appeared normal without structural and morphological alterations or
showed very mild signs of inflammation (Fig 1A–1D).
Regardless of the group, histological scores increased after TNBS treatment (Mdn = 1,
IQR = 1–3, and Mdn = 4, IQR = 2–4 pre- and post-TNBS, respectively; P = 0.055), while the
comparison between groups showed the highest values for CN group (Mdn = 3, IQR = 3–4,
and Mdn = 1, IQR = 0–2 in CN and BC groups, respectively; P = 0.024).
Histological lesions of the colon of CN post-TNBS mice, resembling IDB, showed a severe
grade of inflammation characterized by architectural distortion of the colonic mucosa, ero-
sions of the epithelium, and crypt loss accompanied by a mixed inflammatory infiltrate with
lymphocytes and polymorphonuclear cells (neutrophils and eosinophils granulocytes) in the
epithelium, lamina propria, and submucosal layer. Inflammation also partially involved the
muscular layer (Fig 2E and 2F). On the other hand, colon histology of BC post-TNBS mice
showed evidence of a mild to moderate grade of inflammation characterized by infiltration of
the mucosa and submucosa by lymphocytes and neutrophilic granulocytes (Fig 2G and 2H).
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TLR4 and cytokines gene expression profiling
The administration of TNBS increased the expression TLR4 (marginal means: 15.3±20.4 and
115.0±20.4 before and after TNBS, respectively; P<0.01). The normalized value of TLR4
Fig 1. Colon histology before TNBS administration. Comparative assessment of histological aspects from mice
treated for 21 days with saline solution (A. General view; B. Detailed aspect; Histological score 2) and Bovine
Colostrum (C. General view; D. Detailed aspect; Histological score 1) before the TNBS administration. Both sections
revealed a normal structure of the colon with very mild inflammation of the mucosa. H&E stained, magnification of 4x
(A-C) and 10x (B-D).
https://doi.org/10.1371/journal.pone.0202929.g001
Fig 2. Colon histology after TNBS administration. Comparative assessment of histological aspects of mice treated for
21 days with saline solution (E. General view; F. Detailed aspect; Histological score 4) and Bovine Colostrum (G.
General view; H. Detailed aspect; Histological score 3) after the treatment with TNBS. The saline solution group (E-F)
showed a severe architectural modification of the mucosa, with focal destruction of the epithelium and crypt loss
associated with an inflammatory reaction characterized by severe infiltration of lymphocytes and polymorphonuclear
cells (neutrophils and eosinophils granulocytes) in epithelium, lamina propria and submucosal layers. Inflammation
also involves partially the muscular layer. Colon of Bovine Colostrum group (G-H) showed evidence of a mild to
moderate architectural modification of the mucosa, ulceration of the epithelium, crypt loss accompanied by a mild
inflammatory reaction with infiltration of lymphocytes, a few neutrophils and eosinophils granulocytes in lamina
propria and submucosa layers. H&E stained, magnification of 4x (E-G) and 10x (F-H).
https://doi.org/10.1371/journal.pone.0202929.g002
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expression differed between groups with lower expression in BC than CN group (P = 0.030;
Fig 3). The relative gene expression value was 0.32 (comparative 2^-ΔΔCt method).
Significant effects of TNBS treatment (P<0.001), Group (P<0.001), and interaction
between TNBS and Group (P<0.001) were found for IL-1β, IL-8, and IL-10 mRNA expres-
sions. Marginal means of IL-1β (1.4±0.4 and 6.8±0.4 before and after TNBS, respectively;
P<0.001), IL-8 (2.5±1.2 and 14.9±1.2 before and after TNBS, respectively; P<0.001), and IL-
10 (2.2±4.9 and 41.5±4.9 before and after TNBS, respectively; P<0.001) were higher after
TNBS treatment. Moreover, pairwise comparisons showed higher values of normalized values
in CN than BC group after TNBS treatment (P<0.001; Fig 4 Panel A-C). The fold change in
the target gene normalized to ACTB and relativized to CN gene expression, calculated for IL-
1β, IL-8, and IL-10 sample were respectively 0.29, 0.24, and 0.27 fold change in expression.
A high variability of the expression of TNF-α as well as the effect of neither the group nor
treatment were found (Fig 4D).
Gut microflora
Overall, treatment with TNBS determined an increase in E. coli (P<0.01) and Enterococci
(P<0.001) as well as a reduction in Anaerobes (P<0.01), Lactobacilli (P<0.001), and Bifido-
bacteria (P<0.001; S3 Table). Group effect showed that estimated marginal means of E. coli
(P<0.001) and Enterococci (P<0.001) were higher in CN than BC group; whereas, Lactobacilli
were higher in BC group (P<0.01). Moreover, TNBS resulted in a different response of the
mice receiving colostrum for the all the bacteria examined (significant effects for interaction
between Group and TNBS treatment: P< 0.05 for Enterococci and Anaerobes; P< 0.001 for
Fig 3. Impact of TNBS treatment on mRNA expression of TLR4 (2^-ΔCt) in Control and Bovine Colostrum (BC)
groups. P<0.05. Control vs BC group before (Pre) and after (Post) TNBS treatment.
https://doi.org/10.1371/journal.pone.0202929.g003
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E. coli, Lactobacilli and Bifidobacteria). In particular, after TNBS treatment, no significant
changes were found in BC group; conversely, E. coli and Enterococci increased (P<0.001),
while Anaerobes (P = 0.001), Lactobacilli, and Bifidobacteria (P<0.001) decreased in CN
group (Fig 5 Panel A-E).
Discussion
Colostrum contains several biologically active substances such as growth and immunomodula-
tory factors, Igs, and antimicrobial peptides that retain their activity while passing the gastroin-
testinal tract carrying out beneficial effect on the intestinal functions [35,36,48]. Colostrum
and colostrum derived products have been used for the prevention and treatment of several
gastrointestinal disorders [39,41,42,44,49,50]. However, experimental trials for the treatment
of IBD are still limited. Thus, in our study, we determined whether the oral administration of
BC may prevent the clinical signs in a murine model of TNBS-induced colitis using a multidis-
ciplinary approach.
Our study showed that BC administration was well tolerated and did not induce any dam-
age or pathological symptoms. In particular, we did not observe BW loss, changes in intestinal
microbiota, histological score, and DAI before the treatment with TNBS. According to the cur-
rent state of knowledge, BC appears to be safe and no contraindications are observed even
when it is administered in high concentrations both in humans and animals [44,51,52]. Only a
few studies have reported lactose intolerance, nausea, flatulence, transient diarrhoea, and
unspecified abdominal discomfort as possible side effects [49,53].
Fig 4. Impact of TNBS treatment on mRNA expression of IL-1β, IL-8, IL-10, and TNF-α (2^-ΔCt; Panel A-D) in
control and Bovine Colostrum (BC) groups. P<0.001. Control vs BC group before (Pre) and after (Post) TNBS
treatment.
https://doi.org/10.1371/journal.pone.0202929.g004
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The key finding of our study was that the preventive BC administration reduced the clinical
signs in TNBS-induced colitis in CD1 mice. In particular, after TNBS treatment, BW loss
appeared to be less severe, and both DAI and histological score were reduced in BC-treated
mice in comparison to control group. Our results are in agreement with other studies con-
ducted in human IBD and in Dextran Sulphate Sodium (DSS)-induced colitis in mice [43,44].
Similar findings were also found in a murine model of TNBS-induced colitis using hyperim-
mune BC although they were different in animals administered with raw BC [54].
There is evidence that both immune system and microbiota are involved in the inflamma-
tory process that leads to intestinal lesions in IBD. In fact, dysbiosis and defects in mucosal
immune functions such as microbe recognition, barrier function, and antimicrobial effector
mechanisms may play a crucial role in the pathogenesis of IBD [5,9]. It is speculated that the
chronic inflammation in IBD could be either a normal immune response to an abnormal
intestinal microbiota or, in other cases, an excessive and aberrant immune response to a nor-
mal commensal flora in genetically susceptible individuals [5,7,9]. LPS from outer membrane
of gram-negative bacteria can induce the activation of the innate immune system binding
TLR4 in immune and non-immune cells. The activation of TLR4 by LPS leads to the induction
of genes that function in the host defense including pro-inflammatory cytokines, chemokines,
and other inflammatory mediators that influence the immune response and make a link
between innate and acquired immunity [15]. As a consequence, an upregulation of TLR4
expression can be involved in the process of abnormal and enhanced inflammatory responses
[18,22,55]. In a murine model of DSS-induced colitis, an increase in mRNA and protein
expression in intestinal epithelial cells for TLR4 that was correlated with IL-1β expression was
demonstrated [21]. Moreover, an up-regulation of TLR4 and pro-inflammatory cytokines was
also found in other studies [56–58]. However, TLR4 responses to LPS of commensal bacteria
also play a crucial role in the maintenance of both the intestinal homeostasis and host tolerance
[8]. Indeed, gut microbial LPS is considered to be a strong activator of the innate immune sys-
tem as well as a component of the microbiota which is able to influence the host physiology.
Finally, LPS tolerance can be considered one of the mechanisms that may control the develop-
ment of IBD preventing an abnormal activation of the immune system [59]. For this reason,
Fig 5. Impact of TNBS treatment on E. coli, Enterococci, Anaerobes, Lactobacilli, and Bifidobacteria count (Panel
A-E) in control and Bovine Colostrum groups. Values are mean±SE. P<0.05, P<0.001. Control vs Bovine
Colostrum group before (Pre) and after (Post) TNBS treatment.
https://doi.org/10.1371/journal.pone.0202929.g005
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the down-regulation of TLR4 expression and/or a negative regulation of their intra-cellular
signalling pathways and functions could be necessary [60–62].
In this context, another remarkable finding of our study was that the prophylactic adminis-
tration of BC reduced both the gene expression of TLR4 (0.32 fold change) and of some pro-
inflammatory cytokines such as Il-1β (0.29 fold change) and IL-8 (0.24 fold change) after the
treatment with TNBS compared to the control group. These results are consistent with previ-
ous reports in which BC reduced the protein expression not only of TLR4 but also of different
pro-inflammatory cytokines such as L-1β, IL-8, and TNF-α in the small intestine of preterm
pigs [42]. Moreover, it appears that BC whey protects the integrity of the intestinal mucosal
barrier by inhibiting the expression levels of inflammatory genes following the invasion by
enteric bacterial pathogens [63,64]. Colostrum proteins inhibit NF-κB-mediated pro-inflam-
matory cytokine expression and switch off markers of inflammation [65]. An inhibition of
pro-inflammatory cytokines was also reported in a DSS model using Balb mice administered
with colostrum whey and other components of milk [66]. Finally, in an in vitro study, An et al.
[67] showed that colostrum blocks IL-1β-induced pro-inflammatory gene expression and
COX-2 protein expression in human colon cancer cell line HT-29 through an inhibition of
NF-κB signaling pathway. Similar results were also found in mice [38]. Moreover, BC contains
considerable high levels of IgG that may be increased by the vaccination of the cows during
pregnancy with the aim to enhance the concentrations of specific antibodies [68,69]. The cen-
tral role of Igs in the intestine is to bind the bacteria, in particular the pathogens, with a mecha-
nism called exclusion. In this way, the bacteria can not enter into contact with the intestinal
epithelium and it is reduced the continuous antigenic stimulation from the gut-derived bacte-
rial endotoxin such as LPS, favouring the maintenance of a state of tolerance [70]. Moreover,
Igs can maintain the intestinal barrier functions reducing the risk of inflammation and bacte-
rial translocation [71]. IL-10 is an anti-inflammatory cytokine that plays a crucial role in the
intestinal immune homeostasis. Indeed, IL-10 deficiency leads to the development of colitis in
mice [72]. The inhibitory cytokines IL-10, TGFβ and IL-35 are considered to be Tregs pivotal
mechanism of annihilating pro-inflammatory cytokines secretion of other immune cell types
[73,74]. Our results showed an increase of IL-10 expression after TNBS treatment both in con-
trol and BC groups of mice although the control group showed a higher value. In a previous
study, hyperimmune BC, although not raw colostrum, promoted the increase of Tregs and the
serum levels of IL-10 in mice [54]. On the other hand, previous data did not reveal a significant
increase of IL-10 in mice prophylactically treated with BC [75].
In the host, intestinal microbiota play crucial roles not only in inhibiting colonization by
several pathogens but also in conferring mucosal barrier as well as metabolic and immune reg-
ulatory functions [6,8,10]. It is believed that specific bacteria in the gut microbiota such as Lac-
tobacilli and Bifidobacteria can regulate and direct both the barrier functions and the activity
of the immune system contributing to the maintenance of the intestinal homeostasis [38]. For
these reasons, the manipulation of the intestinal flora favouring the development of specific
bacterial strains that can impact immune function counteracting the dysbiosis and the result-
ing inflammation can be an attractive strategy of clinical interest [10,76]. BC contains abun-
dant concentrations of oligosaccharides such as fructo-oligosaccharides and beta-galacto-
oligosaccharides [77], gangliosides [78], and nucleosides [79] which have been claimed to ben-
efit the health of the colon by selectively stimulating the growth of beneficial bacteria acting as
prebiotics. In our study, the administration of TNBS in the control group created an imbalance
of intestinal microbiota, which is similar to that observed in IBD, consisting in the increase of
E. coli population and in the decrease of Lactobacilli and Bifidobacteria. In fact, similar results
were found in IBD patients and in TNBS induced colitis in mice [76] which presented a reduc-
tion in the biodiversity and a depletion of both some bacterial phyla in feces and mucosa-
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associated microbiota compared to healthy individuals [12,13]. On the other hand, BC admin-
istration seems to preserve the intestinal microbiota, especially the beneficial bacteria. We can,
thus, hypothesize that BC can stabilize intestinal microbiota favouring the growth of beneficial
bacteria which in turn may contribute to reinforce the mucosal barrier function and to modu-
late the immune response reducing the severity of the inflammatory reaction. As previously
mentioned, the beneficial gram-negative bacteria increases the nonimmunogenic LPS concen-
tration that may reduce the cell surface expression level of the LPS receptor complex and there-
fore the activation of the TLR4 signalling pathway. This downregulation contributes to the
maintenance of the immunological tolerance state. Indeed, a recent study showed that a proin-
flammatory cellular pathway that is usually activated by pathogenic bacteria is actively
repressed by some bacteria species of the intestinal microbiota; this contributes to the idea that
beneficial microbes play a role in the establishment of immune tolerance and homeostasis in
the gut [80]. Moreover, some gram-negative bacteria are able to produce antagonistic forms of
LPS which can inhibit TLR4 signaling while some commensal bacteria and pathogens are able
to produce LPS variants that prevent the inflammatory endocytosis of TLR4 mediated by
CD14 [81,82].
Our results are in accordance with recent studies which provided evidence that BC admin-
istration might balance the indigenous microbiota [64,83–85]; however, other studies reported
no detectable difference in gut bacterial composition in piglets treated with hyperimmune BC
[86].
Conclusion
Bovine colostrum is a rich source of biologically active molecules that are essential for several
specific functions of digestive system and, at the same time, that can synergistically intervene
in various pathogenetic phases of the IBD. BC may has the potential to modulate the immuno-
logical response as well as the severity of the intestinal inflammatory reaction modulating
TLR4 and cytokine expression, reducing BW loss and histological score, balancing the micro-
biota, and finally decreasing the clinical signs of colitis in mice. Moreover, BC seems a suitable
candidate to be used as a natural supplement that may reduce the side effects of the synthetic
drugs that are currently used in the treatment of IBD and other digestive system diseases
although its effectiveness and safety still need to be demonstrated.
Despite the encouraging results, further studies are required not only to confirm the effec-
tiveness and safety of BC but also to clarify the immunomodulatory mechanisms that can pre-
vent the development and the progression of the chronic inflammation in IBD.
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